Zoe, a London-based nutrition company, is expanding its presence in the United States after securing $15 million in a Series B extension, bringing its total funding to $118 million. Zoe's unique approach to personalized health and weight loss combines at-home testing with customized nutrition recommendations, targeting the gut microbiome, blood sugar, and blood fat.
Zoe's expansion in the US is fueled by a robust scientific foundation. The company has published over 60 peer-reviewed scientific papers, including a randomized controlled trial published in Nature Medicine in May 2024. This trial, which compared Zoe's program to standard dietary guidelines, demonstrated that Zoe's personalized nutrition approach effectively improved cardiometabolic health and overall well-being.
Zoe's focus on personalized nutrition addresses a critical gap in the field. Traditional dietary advice often lacks the individualized approach required for optimal health. Zoe's platform leverages cutting-edge science to provide personalized recommendations tailored to each user's unique needs and health goals.
Zoe's new funding will enable the company to expand its reach in the US market, leveraging the growing consumer demand for personalized health solutions. The company plans to invest in marketing initiatives to reach a wider audience and further its mission of empowering people to make informed choices about their nutrition.
Zoe is at the forefront of personalized health, offering a unique combination of at-home testing, personalized nutrition recommendations, and a commitment to scientific rigor. By addressing the individual needs and health goals of its users, Zoe empowers people to make informed choices about their nutrition, leading to improved health outcomes and overall well-being.
Ask anything...